ClonoScreen3D – a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma

Glioblastoma (GBM) is a lethal brain tumor. Standard of care treatment comprising surgery, radiation and chemotherapy results in median survival rates of 12-15 months. Molecular targeted agents identified using conventional two-dimensional (2D) in vitro models of GBM have failed to improve outcome in patients, rendering such models inadequate for therapeutic target identification. A previously developed 3D GBM in vitro model that recapitulates key GBM clinical features and responses to molecular therapies was investigated for utility for screening novel radiation-drug combinations using gold-standard clonogenic survival as readout.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research